Market Overview

Novo Nordisk to Initiate Phase 3 Development of Semaglutide

Novo Nordisk (NYSE: NVO) today announced the decision to initiate the global phase 3 development programme for semaglutide, a once-weekly human GLP-1 (Glucagon-Like Peptide-1) analogue.

Posted-In: News FDA

 

Related Articles (NVO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters